Liberty’s Expeditionary Science and Special Programs Laboratory (X-Lab) develops bioengineering and clinical solutions to challenging medical, commercial and industrial unmet needs. These solutions are derived from novel organisms obtained from government and Liberty's own proprietary collection of extremophile biologics. The X-Lab's multidisciplinary team of microbiologists and bioinformaticians are supported by physicians and experts drawn from military and intelligence communities.
Liberty Biosecurity has developed a proprietary biological drug compound that degrades polymicrobial biofilms produced by pathogens in human wounds. Internally designated as Advanced Decontamination and Bio-Neutralization Material (ADBM), this compound is being developed into a portfolio of compound derivatives targeted at multiple types of pathogenic biofilms.
ADBM will be submitted to the U.S. Food and Drug Administration as an Investigative New Drug, with the indication of use as a topical therapy to enhance wound healing in neuropathic diabetic foot ulcers. Globally, this condition afflicts up to 35% of the 422 million people living with diabetes, while in the US alone, diabetic limb complications result in an annual direct cost of $17 billion/year.